Erigen LLC tied to Tempest Therapeutics (TPST) CEO reports 8,268,495 shares

Rhea-AI Filing Summary

Tempest Therapeutics CEO and President Matthew Angel, who also serves as a director and 10% owner of Tempest Therapeutics, Inc., filed an initial Form 3. The filing reports 8,268,495 shares of common stock held indirectly through Erigen LLC.

The shares are owned by Erigen LLC, where Angel is a member, and he disclaims beneficial ownership of these securities except for his proportionate pecuniary interest. This filing establishes his indirect ownership position under Section 16 reporting rules.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Angel Matthew

(Last) (First) (Middle)

C/O TEMPEST THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 400

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/03/2026

3. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	8,268,495	I	By Erigen LLC(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares are held by Erigen LLC (the "LLC"). The Reporting Person is a member of the LLC and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

	/s/ Matthew Angel	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Tempest Therapeutics (TPST) Form 3 filed by Matthew Angel report?

The Form 3 reports that 8,268,495 Tempest Therapeutics common shares are held indirectly through Erigen LLC. Matthew Angel, the company’s CEO, President, director, and 10% owner, is a member of that LLC and files this as his initial ownership statement.

How many Tempest Therapeutics (TPST) shares are held by Erigen LLC in this filing?

Erigen LLC is reported as holding 8,268,495 shares of Tempest Therapeutics common stock. These shares are shown as indirectly beneficially owned in the Form 3, with Matthew Angel identified as a member of the LLC for Section 16 reporting purposes.

Is the Tempest Therapeutics (TPST) CEO shown as a direct shareholder in this Form 3?

No, the shares are reported as indirectly owned through Erigen LLC. The Form 3 indicates the 8,268,495 common shares are held by the LLC, not directly by Matthew Angel, who is listed as a member of the LLC.

What ownership roles does Matthew Angel hold at Tempest Therapeutics (TPST)?

Matthew Angel is identified as CEO, President, director, and a 10% owner of Tempest Therapeutics. These roles appear in the Form 3 header, which ties his reporting obligation to the indirect common stock position held via Erigen LLC.

Does Matthew Angel fully claim beneficial ownership of the Erigen LLC TPST shares?

No, he expressly disclaims beneficial ownership of the Erigen LLC shares, except for his proportionate pecuniary interest. The footnote clarifies that while he is a member of the LLC, he does not claim full beneficial ownership of all 8,268,495 shares.

What type of security is reported in the Tempest Therapeutics (TPST) Form 3?

The Form 3 reports holdings of Tempest Therapeutics common stock. A total of 8,268,495 common shares are listed in Table I as indirectly owned through Erigen LLC, with no derivative securities reported in Table II in this filing excerpt.